{"doi":"10.1093/ofid/ofae574","title":"Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV","abstract":"Abstract Background Among people with HIV (PWH), COVID-19 is common and potentially severe. We leveraged REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) to assess the effects of statin therapy for cardiovascular disease prevention on COVID-19 outcomes (incidence and serious cases) among a global cohort of PWH. Methods COVID-19 data collection was implemented April 2020 to capture events from January 2020. COVID-19 was defined by positive test result or clinical diagnosis and serious COVID-19 according to the International Conference on Harmonisation definition. Among participants in follow-up on 1 January 2020, Cox proportional hazards modeling was used to estimate the hazard ratio (HR) of COVID-19 (pitavastatin/placebo), stratified by Global Burden of Disease region. Modification of statin effect following COVID-19 vaccination was evaluated via interaction with time-updated vaccination status. Results Among 6905 PWH, 32% were natal female and 41% were Black or African American. The median age was 53 years and the 10-year atherosclerotic cardiovascular disease risk score 4.5%. Statin therapy did not reduce COVID-19 incidence (HR, 1.05; 95% CI, .95–1.15) but appeared to reduce incidence of serious COVID-19 (HR, 0.75; 95% CI, .52–1.09). Among 1701 PWH with COVID-19, the relative risk (pitavastatin/placebo) for serious COVID-19 was 0.73 (95% CI, .52–1.03). The treatment effect size for serious COVID-19 fell within the hypothesized range, but the 95% CI crossed 1 given fewer-than-anticipated cases (117 vs 200). Furthermore, 83% reported COVID-19 vaccination by end of study, with a strong protective effect on serious COVID-19 (HR, 0.27; 95% CI, .14–.53; P < .0001). A protective statin effect was observed prior to vaccination. Conclusions Among PWH, statin therapy had no effect on COVID-19 incidence but showed potential to reduce risk of serious COVID-19 prior to COVID-19 vaccination. Clinical Trials Registration NCT02344290 (ClinicalTrials.gov).","journal":"Open Forum Infectious Diseases","year":2024,"id":479117,"datarank":0.20687577926278455,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.042083935962568104,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.042083935962568104,"corpus_percentile":35.1048193703102,"corpus_rank":8388,"citation_count":2,"citer_count":2,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.5457,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02344290"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":476483,"name":"Triin Umbleja","orcid":"0000-0001-7161-7743","position":1,"is_corresponding":false},{"id":335272,"name":"Carl J. Fichtenbaum","orcid":"0000-0002-6778-7253","position":2,"is_corresponding":false},{"id":381594,"name":"Kathleen V. Fitch","orcid":"0000-0002-0541-3707","position":3,"is_corresponding":false},{"id":759908,"name":"Sara McCallum","orcid":"0000-0002-0289-1295","position":4,"is_corresponding":false},{"id":12096,"name":"Judith A. Aberg","orcid":"0000-0001-8162-0284","position":5,"is_corresponding":false},{"id":437399,"name":"Edgar T. Overton","orcid":"0000-0002-4013-536X","position":6,"is_corresponding":false},{"id":380908,"name":"Carlos Malvestutto","orcid":"0000-0003-3156-2965","position":7,"is_corresponding":false},{"id":329844,"name":"Gerald S. Bloomfield","orcid":"0000-0002-7176-1611","position":8,"is_corresponding":false},{"id":396976,"name":"Judith S. Currier","orcid":"0000-0003-4279-4737","position":9,"is_corresponding":false},{"id":489207,"name":"Samuel R Schnittman","orcid":"0000-0002-9692-4405","position":10,"is_corresponding":false},{"id":242505,"name":"Kristine M. Erlandson","orcid":"0000-0003-0808-6729","position":11,"is_corresponding":false},{"id":1015265,"name":"Marissa R Diggs","orcid":null,"position":12,"is_corresponding":false},{"id":282486,"name":"Borek Foldyna","orcid":"0000-0002-2466-4827","position":13,"is_corresponding":false},{"id":12066,"name":"Estebán Martínez","orcid":"0000-0002-6911-8846","position":14,"is_corresponding":false},{"id":380844,"name":"Charurut Somboonwit","orcid":"0000-0001-6210-7231","position":15,"is_corresponding":false},{"id":608731,"name":"Gary P. Wang","orcid":"0000-0002-3457-442X","position":16,"is_corresponding":false},{"id":441491,"name":"David Mushatt","orcid":"0000-0003-2875-902X","position":17,"is_corresponding":false},{"id":809384,"name":"Elizabeth Connick","orcid":"0000-0002-0465-6248","position":18,"is_corresponding":false},{"id":282485,"name":"Michael T. Lu","orcid":"0000-0003-4696-9610","position":19,"is_corresponding":false},{"id":282488,"name":"Pamela S. Douglas","orcid":"0000-0001-9876-4049","position":20,"is_corresponding":false},{"id":396977,"name":"Heather J. Ribaudo","orcid":"0000-0002-0394-3990","position":21,"is_corresponding":false},{"id":12007,"name":"Steven Grinspoon","orcid":"0000-0002-6338-000X","position":22,"is_corresponding":false},{"id":381595,"name":"Markella V. Zanni","orcid":"0000-0002-4711-3956","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T02:06:50.355747Z","pmid":"39435321","pmcid":"PMC11493083","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}